Study on the relationship between the MDR1 and CYP3A genetic polymorphisms and serum digoxin concentration in 111 patients with chronic heart failure

Abstract

Abstract: AIM: To investigate the impact of MDR1C3435T, CYP3A4^*18B and CYP3A5^*3 genetic polymorphism on serum digoxin concentration in Chinese Han patients with chronic heart failure.METHODS: Drug concentration data of digoxin for a group of 111 unrelated Chinese Han patients with chronic heart failure were retrospectively collected after them taken therapeutic drug monitoring (TDM) of digoxin. And their genotypes of MDR1C3435T, CYP3A4^*18B and CYP3A5^*3 alleles were determined by PCR-RFLP method. We investigated the effect of MDR1C3435T, CYP3A4^*18B and CYP3A5^*3 genetic polymorphism on serum digoxin concentration.RESULTS: In old people (older than 70 years), the serum digoxin concentration in MDR1CC3435 and MDR1TT3435 vs. MDR1TT3435 groups showed a significant difference (P<0.05); But there was no statistical difference on the serum digoxin concentration with CYP3A4^*18B or CYP3A5^*3 genetic polymorphism (P>0.05).CONCLUSION: The effect of MDR1C3435T genetic polymorphism increased the serum digoxin concentration; CYP3A4^*18B or CYP3A5^*3 genetic polymorphism may have no significant effect on the serum digoxin concentration.

Key words: genetic polymorphism, digoxin, MDR1, CYP3A4, CYP3A5

CLC Number:

R968

OUYANG Cang-hong, XIE Juan. Study on the relationship between the MDR1 and CYP3A genetic polymorphisms and serum digoxin concentration in 111 patients with chronic heart failure[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(3): 291-296.

References

[1] Hunt SA,Baker DW,Chin MH,et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult:executive summary:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure)[J]. J Am Coll Cardiol, 2001,38(7):2101-2113.
[2] Hunt SA,Abraham WT,Casey DE Jr,et al. ACC/AHA 2005 guidelineupdate for the diagnosis and management of chronic heart failure in the adult:a report of the American College of Cardiology /American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management ofHeart Failure)[J]. J Am Coll Cardiol, 2005,46:1116-1143.
[3] 周宏灏. 药理学[M]. 北京:科学出版社,2003:239.
[4] 杨宝峰,主编. 药理学(第七版)[M]. 北京:人民卫生出版社,2008:10.
[5] Parker BM,Cusack BJ,Vestal RE. Pharmacokinetic optimization of drug therapy in elderly patients [J]. Drugs Aging,1995,7(1):10-18.
[6] Hoffmeyer S,Burk O,yon Richter O,et al.Functional polymorphisms of the human multidrug-resistance gene:multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo [J].Proc Natl Acad Sci USA,2000,97(7):3473-3478.
[7] 鲁玉珍,胡永芳,翟所迪,邱雯. CYP3A5^*3和CYP3A4^*18B基因多态性对肾移植患者环孢素药代动力学的影响[J]. 中国药理学通报, 2009, 25(3):378-382.
[8] Van Sehaik RH,van der Heiden IP,Van den Anker JN,et al.CYP3A5 variant allele frequencies in Dutch Caucasians[J].Clin Chem, 2002, 48(10): 1668-1671.
[9] Johne A,Kopke K,Gerloff T,et al.Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene[J].Clin Pharmacol Ther,2002,72(5):584-594.
[10] Xu P,Jiang ZP,Zhang BK,et al.Impact of MDR1 haplotypes derived from C1236T,G2677T/A and C3435T on the pharmacokinetics of single-dose oral digoxin in healthy Chinese volunteers[J]. Pharmacology,2008,82(3):221-227.
[11] Liu YT,Hao HP,Liu CX,et al.Drugs as CYP3A probes,inducers,and inhibitors [J].Drug Metab Rev,2007,39(4):699-721.
[12] Lamba JK,Lin YS,Schuetz EG,et al.Genetic contribution to variable human CYP3A -mediated metabolism [J]. Adv Drug Deliv Rev,2002,54(10):1271-1294.
[13] Fukushima-Uesaka H,Saito Y Watanabe H,et al.Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population[J].Hum Mutat,2004,23(1):100.
[14] Hu YF,Tu JH,Tan ZR,et al. Association of CYP3A4^*18B polymorphisms with the pharmacokinctics of cyclosporine in healthy subjects [J].Xenobiotica,2007,37(3):315-327.
[15] Kuehl P,Zhang J,Lin Y,et al.Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression [J].Nat Genet,2001,27(4):383-391.
[16] Huang W,Lin YS,McConn DJ,et al.Evidence of significant contribution from CYP3A5 to hepatic drug metabolism [J].Drug Metab Dispos,2004,32(12):1434-1445.
[17] 谷元,司端运,刘昌孝.CYP3A4酶介导的人类药物代谢性别差异[J]. 中国药理学通报,2009,25(9):1121-1124.
[18] 张澈,涂自良,胡永芳,等. CYP3A5基因型的差异对环孢素药代动力学影响的体外研究[J]. 中国药理学通报,2009,25(3):378-382.
[19] Hukkanen J,Vaisanen T,Lassila A,et al.Regulation of CYP3A5 by glucocorticoids and cigarette smoke in human lung-derived cells[J].J Pharmacol Exp Ther,2003,304(2):745-752.
[20] Salphati L,Benet LZ . Metabolism of digoxin and digoxigenin digitoxosides in rat liver microsomes:involvement of cytochrome P450 3A[J]. Xenobiotica,1999,29(2):171-185.
[21] Greiner B,Eichelbaum M,Fritz P,et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin[J]. J Clin Invest,1999,104(2):147-153.